JW Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	775,298	719,376	748,527	684,351	606,585
Other Revenue	-0	-0	-0	-	-
Revenue	775,298	719,376	748,527	684,351	606,585
Revenue Growth (YoY)	7.77%	-3.89%	9.38%	12.82%	10.82%
Cost of Revenue	415,984	395,878	412,984	396,397	372,209
Gross Profit	359,314	323,498	335,542	287,955	234,376
Selling, General & Admin	222,622	210,610	204,728	182,652	171,220
Research & Development	45,447	36,237	33,671	33,736	19,884
Operating Expenses	271,437	240,766	238,911	227,464	203,528
Operating Income	87,877	82,733	96,631	60,490	30,848
Interest Expense	-4,424	-10,033	-12,562	-9,387	-7,337
Interest & Investment Income	3,338	4,962	6,322	5,814	1,981
Earnings From Equity Investments	2,259	1,387	621.06	-955.41	-1,149
Currency Exchange Gain (Loss)	-618.56	1,087	-1,817	-2,300	-925.96
Other Non Operating Income (Expenses)	-1,126	2,253	-36,102	5,425	-1,191
EBT Excluding Unusual Items	87,305	82,390	53,095	59,088	22,227
Gain (Loss) on Sale of Investments	1,578	790.9	2,830	-8,908	-646.8
Gain (Loss) on Sale of Assets	-46.76	464.91	-1,088	3.28	-1,048
Asset Writedown	-	-1,476	-	-4,821	-
Other Unusual Items	-	249.74	-	-	-
Pretax Income	88,836	82,420	54,836	45,362	20,533
Income Tax Expense	27,325	17,379	16,406	15,509	21,974
Earnings From Continuing Operations	61,511	65,040	38,430	29,853	-1,441
Minority Interest in Earnings	-	-	-1,424	2,039	473.6
Net Income	61,511	65,040	37,006	31,892	-967.85
Net Income to Common	61,511	65,040	37,006	31,892	-967.85
Net Income Growth	-5.43%	75.75%	16.04%	-	-
Shares Outstanding (Basic)	24	25	24	23	23
Shares Outstanding (Diluted)	24	25	24	23	23
Shares Change (YoY)	-1.32%	3.34%	2.49%	0.07%	-0.05%
EPS (Basic)	2534.00	2644.00	1554.67	1373.14	-41.70
EPS (Diluted)	2534.00	2644.00	1554.67	1373.14	-41.70
EPS Growth	-4.16%	70.07%	13.22%	-	-
Free Cash Flow	84,625	71,079	59,871	46,845	10,657
Free Cash Flow Per Share	3486.17	2889.49	2515.25	2016.97	459.20
Gross Margin	46.34%	44.97%	44.83%	42.08%	38.64%
Operating Margin	11.34%	11.50%	12.91%	8.84%	5.08%
Profit Margin	7.93%	9.04%	4.94%	4.66%	-0.16%
Free Cash Flow Margin	10.91%	9.88%	8.00%	6.84%	1.76%
EBITDA	106,624	101,834	119,206	77,327	46,960
EBITDA Margin	13.75%	14.16%	15.93%	11.30%	7.74%
D&A For EBITDA	18,748	19,101	22,575	16,836	16,112
EBIT	87,877	82,733	96,631	60,490	30,848
EBIT Margin	11.34%	11.50%	12.91%	8.84%	5.08%
Effective Tax Rate	30.76%	21.09%	29.92%	34.19%	107.02%
Advertising Expenses	22,691	24,252	22,690	22,673	18,416

Source: S&P Global Market Intelligence. Standard template. Financial Sources.